Yves Fradet

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.3K citations · Full text

Widespread and Functional RNA Circularization in Localized Prostate Cancer

Sujun Chen, Vincent Huang, Xin Xu et al. · Cell · 2019 · 674 citations · Full text

Functional Rna Circularization, Prostatic Disease, Systems Biology +3

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Genomic hallmarks of localized, non-indolent prostate cancer

Michael Fraser, Veronica Y. Sabelnykova, Takafumi N. Yamaguchi et al. · Nature · 2017 · 624 citations

Urology, Cancer Genomics, Prostatic Disease +3

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles, Michiel S. van der Heijden, Daniel Castellano et al. · The Lancet Oncology · 2020 · 485 citations · Full text

Surgical Oncology, Urology, Metastatic Urothelial Carcinoma +8